01 — At a Glance
The CDMO Betting Everything on One Drug’s Approval
- 52-Week High / Low₹2,250 / ₹1,057
- Q3 FY26 Revenue₹290 Cr
- Q3 FY26 Loss-₹89 Cr
- 9M FY26 Revenue₹993 Cr
- 9M FY26 PAT Loss-₹78 Cr
- Book Value₹515
- Debt / Equity0.68x
- Interest Coverage1.01x
- Dividend Yield0.00%
- Capex Planned~₹700 Cr+
⚠️ The Brutal Truth: OneSource was supposed to be the next global CDMO unicorn. IPO at ₹801 crore raised in November 2024. Stock rode euphoria to ₹2,250 in January 2026. Then Q3 results landed: revenue missed by ₹400+ crores. GLP-1 customers in Canada — the entire thesis — received regulatory approval delays. Semaglutide manufacturing delayed. Customers paused orders. Now the stock sits at ₹1,479, down 34% from peak. And management says “next two quarters will remain soft.” Welcome to manufacturing concentration risk with a side of regulatory dependency.
02 — Introduction
Contract Manufacturing: Where Dreams Come to Sit in Warehouses
OneSource Specialty Pharma is what happens when a pharmaceutical conglomerate (Strides Pharma) decides to create a Contract Development and Manufacturing Organization (CDMO) by stitching together three separate businesses: sterile injectables, soft gelatin capsules, and biologics. The demerger was approved in April 2024. The IPO happened 7 months later at a valuation that valued the company at nearly $2 billion. The stock tripled by January. Then reality caught up.
Q3 FY26 delivered the goods — or rather, didn’t. Revenue collapsed 26% year-over-year to ₹290 crore. Operating profit nosedived to ₹17 crore. Net loss: ₹89 crore. In a single quarter, the company erased the narrative.
The culprit? Not operational failure. Regulatory failure. OneSource had pinned its entire short-term growth story on GLP-1 semaglutide manufacturing for Canadian customers. Canada’s regulatory approval came late. Very late. Customers deferred orders. OneSource, showing “partnership mentality,” chose not to enforce take-or-pay clauses strictly. Capacity built with no customers to fill it. Fixed costs kept running. Profitability evaporated.
The management concall in January 2026 was brutally candid: “the next two quarters will remain relatively soft.” Translation: Q4 and Q1 will be worse. But the narrative pivots to FY27-FY28, when CSAs (Commercial Supply Agreements) will commence and the ₹700+ crore capex build-out will translate into utilization and cash generation.
So the question isn’t “is this a good company?” The question is: “Will semaglutide customers materialize in the volumes promised, and can OneSource execute a ₹700+ crore capex expansion without destroying returns?” If yes: generational compounding. If no: a CDMO with a debt burden it can’t service.
Concall Context (Jan 2026): “Semaglutide delays were the elephant in the room… Canada was the only large market to operate at scale… Several partners did not receive approval.” — Management, Q3 FY26 Earnings Call. Canadian approvals now expected “anytime between now and May.” Every week of delay is ₹4-5 crore in missing revenue.
03 — Business Model: CDMO, Spelled C-O-N-C-E-N-T-R-A-T-I-O-N-R-I-S-K
They Make Drugs. For Other People. And Hope Those People Succeed.
OneSource isn’t a pharmaceutical company. It’s a contract manufacturer for pharmaceutical companies — like an outsourced factory with a regulatory stamp. The business model: biopharma customers come to OneSource, say “we need you to manufacture our GLP-1 semaglutide for markets X, Y, Z,” and OneSource builds capacity, manufactures at scale, and collects fees as products launch and commercialize.
Simple, right? Wrong.
The business is split across three modalities: Drug-Device Combinations (DDC — think GLP-1 pens), Biologics (biosimilars, monoclonal antibodies), and Soft Gelatin Capsules (oral drug delivery). DDC is the headline — GLP-1 semaglutide, tirzepatide — the $100+ billion market where everyone and their venture fund wants to play. OneSource had capacity. Customers lined up. Revenue was supposed to compound 40%+ annually through FY28.
Then the customers’ regulators (Canada, European agencies) delayed approval. The approvals gate everything. No approval = no sales = no revenue = no utilization of the ₹700+ crore capacity that OneSource just spent ₹400 crores to build. The company is now running at 27% of stated capacity utilization in Q3, with “fixed costs” remaining inflexible. Hence the loss.
But there’s a twist: Management holds ~₹250 crore in customer advances, pre-booked for capacity. The advances are real deposits for future manufacturing. Which means: if customers follow through, revenue will be enormous. If they don’t — or if their products fail — that advance becomes a contingent liability disguised as a balance-sheet asset.
DDC Capacity220MUnits Target FY28
Biologics6KLMicrobial Capacity
Cartridges40M→100MExpansion Underway
Customer Advances₹250 CrPre-booked Capacity
The Concall Quote That Defined It: “We decided to prioritise our capacities for commercial sales… when we move from MSAs to commercials, we obviously make more economics.” MSA = Manufacturing Service Agreement (development, low-volume). CSA = Commercial Supply Agreement (full-scale production). The company literally paused new MSA contracts in Q3 to preserve capacity for future CSAs. It’s strategically sound. But it killed near-term profitability.
💬 Here’s the tension: If approvals come in May as promised, will one-quarter of revenue deferral destroy the long-term thesis? Or is it a hiccup on the way to ₹4,000 crore annual revenues by FY28? Drop your view.
04 — Financials Overview
Q3 FY26: The Quarter That Broke The Honeymoon
Result type: Quarterly Results | Q3 FY26 EPS: ₹-7.74 | Annualised EPS (Q3×4): -₹30.96 | 9M FY26 PAT: -₹78 Cr
| Metric (₹ Mn) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 2,903 | 3,933 | 3,757 | -26.0% | -22.7% |
| Operating Profit | 173 | N/A | 1,050 | N/A | -83.5% |
| OPM % | 6% | ~20% | 28% | -1400 bps | -2200 bps |
| PAT (Loss) | -887 | -1,093* | 105 | +19% | -942% |
| EPS (₹) | -7.74 | N/A | 0.92 | N/A | -942% |
The Carnage Breakdown: Q3 revenue of ₹290.3 crore is down 26% YoY from ₹393.3 crore in Q3 FY25. But the real disaster is margins. Operating profit collapsed from ₹104.2 crore (Q2) to ₹17 crore (Q3). The operating margin compressed from 28% to 6% — a 2,200 basis point free-fall in a single quarter. Why? Because OneSource has high fixed costs in manufacturing (depreciation ₹70 crore/quarter, interest ₹34-38 crore/quarter, rent, utilities) that don’t scale down when customers defer orders. Revenue fell ₹10 crore QoQ, but EBITDA fell ₹85 crore. That’s operational leverage in reverse — the nightmare scenario for capital-intensive businesses. PAT swung from ₹10.5 crore profit (Q2) to ₹-88.7 crore loss (Q3). A ₹1,000 crore quarter-on-quarter swing.
05 — Valuation Discussion: Fair Value Range Only
Valuing A Company With Uncertain Revenue Visibility
Join 10,000+ investors who read this every week.
